Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Buckwheat and Cardiometabolic Health: A Systematic Review and Meta-Analysis Publisher



Llanaj E1, 2, 3 ; Ahanchi NS4 ; Dizdari H4 ; Taneri PE4, 5, 6 ; Niehot CD7 ; Wehrli F4, 8 ; Khatami F4, 8 ; Raeisidehkordi H4, 9 ; Kastrati L4, 9 ; Bano A4, 10 ; Glisic M4, 11 ; Muka T2, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrucke, Nuthetal, 14558, Germany
  2. 2. Bern, Epistudia, 3012, Switzerland
  3. 3. ELKH-DE Public Health Research Group of the Hungarian Academy of Sciences, Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Kassai ut 26, Debrecen, 4028, Hungary
  4. 4. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, 3012, Switzerland
  5. 5. School of Nursing and Midwifery, National University of Ireland Galway, Galway, H91 TK33, Ireland
  6. 6. HRB-Trials Methodology Research Network, Galway, H91 TK33, Ireland
  7. 7. Literature Searches Support, Dordrecht, 3311, Netherlands
  8. 8. Department of Community Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, 1416634793, Iran
  9. 9. Graduate School for Health Sciences, University of Bern, Bern, 3012, Switzerland
  10. 10. Department of Cardiology, University Hospital of Bern, University of Bern, Bern, 3012, Switzerland
  11. 11. Swiss Paraplegic Research, Nottwil, 6207, Switzerland

Source: Journal of Personalized Medicine Published:2022


Abstract

Buckwheat (BW) is suggested to have beneficial effects, but evidence on how it affects cardiometabolic health (CMH) is not yet established. We aimed to assess the effects of BW and/or its related bioactive compounds on cardiovascular disease (CVD) risk markers in adults. Five databases were searched for eligible studies. Observational prospective studies, nonrandomized or randomized trials were considered if they assessed BW, rutin or quercetin-3-glucoside intake and CVD risk markers. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting. We selected 16 human studies based on 831 subjects with mild metabolic disturbances, such as hypercholesterolemia, diabetes and/or overweight. Eight studies, investigating primarily grain components, were included in the meta-analyses (n = 464). High study heterogeneity was present across most of our analyses. Weighted mean difference (WMD) for subjects receiving BW supplementation, compared to controls, were − 0.14 mmol/L (95% CI: −0.30; 0.02) for total cholesterol (TC), −0.03 mmol/L (95% CI: −0.22; 0.16) for LDL cholesterol, −0.14 kg (95% CI: −1.50; 1.22) for body weight, −0.04 mmol/L (95% CI: − 0.09;0.02) for HDL cholesterol, −0.02 mmol/L (95% CI: −0.15; 0.11) for triglycerides and −0.18 mmol/L (95% CI: −0.36; 0.003) for glucose. Most of the studies (66.7%) had concerns of risk of bias. Studies investigating other CVD markers were scarce and with inconsistent findings, where available. Evidence on how BW affects CMH is limited. However, the available literature indicates that BW supplementation in mild dyslipidaemia and type 2 diabetes may provide some benefit in lowering TC and glucose, albeit non-significant. Our work highlights the need for more rigorous trials, with better methodological rigor to clarify remaining uncertainties on potential effects of BW on CMH and its utility in clinical nutrition practice. © 2022 by the authors.
Experts (# of related papers)
Other Related Docs
14. Low-Dose Whole Lung Irradiation for Treatment of Covid-19 Pneumonia: A Systematic Review and Meta-Analysis, International Journal of Radiation Oncology Biology Physics (2022)